Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Arboretum Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Arboretum Ventures

Arboretum Ventures

Operating

Arboretum Ventures: A venture capital firm specializing in cost-effective healthcare investments, primarily in the Midwest.

Location
Ann Arbor, MI, US
Founded
2002
Firm
Compare
Portfolio
Fundraising
Employees
Website

Investments

Avation Medical
Avation Medical
Series C

Total Raised

$34.9M

Rounds

2

Series C$22MFebruary 2024
Motif Neurotech
Motif Neurotech
Series A

Total Raised

$18.9M

Rounds

2

Series A$18.8MJanuary 2024
Virtual Incision
Virtual Incision
Series C

Total Raised

$146M

Rounds

12

Series C$30MSeptember 2023
Convergent Dental
Convergent Dental
Series A

Total Raised

$115.2M

Rounds

9

Series Unknown$5MApril 2023
Series C$40MOctober 2021
Cardiac Dimensions
Cardiac Dimensions
Public

Total Raised

$209.7M

Rounds

10

Series D$35MJanuary 2023
Series C$17.5MSeptember 2020
BrightSpec
BrightSpec
Series C

Total Raised

$21.1M

Rounds

5

Series C$18.4MDecember 2022
Boomerang Medical
Boomerang Medical
Series A

Total Raised

$18M

Rounds

2

Series A$15MNovember 2022
Seed$3MOctober 2021
Delphinus Medical Technologies
Delphinus Medical Technologies
Series A

Total Raised

$109.1M

Rounds

6

Series D$30.4MSeptember 2022
Navv Systems
Navv Systems
Series A

Total Raised

$8.7M

Rounds

2

Series A$5.5MAugust 2022
Seed$3.2MJune 2021
Enumera Molecular
Enumera Molecular
Series A

Total Raised

$12.5M

Rounds

1

Series A$12.5MMay 2022
Koya Medical
Koya Medical
Series C

Total Raised

$70.2M

Rounds

6

Series B$26MFebruary 2022
Series A$11MJanuary 2021
Pear Therapeutics
Pear Therapeutics
Public

Total Raised

$409M

Rounds

9

Post Ipo Equity$125MDecember 2021
Series D$80MDecember 2020
ViaLase
ViaLase
Seed

Total Raised

$37.7M

Rounds

3

Series A$27.3MNovember 2021
Akadeum Life Sciences
Akadeum Life Sciences
Series B

Total Raised

$21.5M

Rounds

9

Series B$17.5MOctober 2021
Francis Medical
Francis Medical
Series B

Total Raised

$77M

Rounds

3

Series B$55MSeptember 2021
Allay Therapeutics
Allay Therapeutics
Series C

Total Raised

$118.9M

Rounds

4

Series C$86.9MSeptember 2021
RareCyte
RareCyte
Public

Total Raised

$76M

Rounds

5

Series G$24MSeptember 2021
Strata Oncology
Strata Oncology
Series C

Total Raised

$128M

Rounds

3

Series C$90MJuly 2021
Jumpcode Genomics
Jumpcode Genomics
Series B

Total Raised

$23.5M

Rounds

2

Series B$21MJanuary 2021